BDTX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of 80.77% compared to Black Diamond Therapeutics's net margin of -49.65%. Black Diamond Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Black Diamond Therapeutics has a consensus price target of $10.75, signalling upside risk potential of 234.89%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Black Diamond Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Black Diamond Therapeutics is more attractive than NovaBay Pharmaceuticals.

Black Diamond Therapeutics has a beta of 2.711, which suggesting that the stock is 171.11% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Black Diamond Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Black Diamond Therapeutics quarterly revenues are $70M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Black Diamond Therapeutics's net income of $56.5M is higher than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Black Diamond Therapeutics's price-to-earnings ratio is 53.50x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology has a net margin of 80.77% compared to Black Diamond Therapeutics's net margin of 6.46%. Black Diamond Therapeutics's return on equity of -- beat Puma Biotechnology's return on equity of 52.9%.

Black Diamond Therapeutics has a consensus price target of $10.75, signalling upside risk potential of 234.89%. On the other hand Puma Biotechnology has an analysts' consensus of $3.00 which suggests that it could fall by -12.79%. Given that Black Diamond Therapeutics has higher upside potential than Puma Biotechnology, analysts believe Black Diamond Therapeutics is more attractive than Puma Biotechnology.

Black Diamond Therapeutics has a beta of 2.711, which suggesting that the stock is 171.11% more volatile than S&P 500. In comparison Puma Biotechnology has a beta of 1.287, suggesting its more volatile than the S&P 500 by 28.736%.

Black Diamond Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics pays -- of its earnings as a dividend. Puma Biotechnology pays out -- of its earnings as a dividend.

Black Diamond Therapeutics quarterly revenues are $70M, which are larger than Puma Biotechnology quarterly revenues of $46M. Black Diamond Therapeutics's net income of $56.5M is higher than Puma Biotechnology's net income of $3M. Notably, Black Diamond Therapeutics's price-to-earnings ratio is 53.50x while Puma Biotechnology's PE ratio is 4.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics is -- versus 0.73x for Puma Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 80.77% compared to Black Diamond Therapeutics's net margin of 21.63%. Black Diamond Therapeutics's return on equity of -- beat Pfizer's return on equity of 8.72%.

Black Diamond Therapeutics has a consensus price target of $10.75, signalling upside risk potential of 234.89%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.77%. Given that Black Diamond Therapeutics has higher upside potential than Pfizer, analysts believe Black Diamond Therapeutics is more attractive than Pfizer.

Black Diamond Therapeutics has a beta of 2.711, which suggesting that the stock is 171.11% more volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Black Diamond Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Black Diamond Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Black Diamond Therapeutics quarterly revenues are $70M, which are smaller than Pfizer quarterly revenues of $13.7B. Black Diamond Therapeutics's net income of $56.5M is lower than Pfizer's net income of $3B. Notably, Black Diamond Therapeutics's price-to-earnings ratio is 53.50x while Pfizer's PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics is -- versus 2.25x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 80.77% compared to Black Diamond Therapeutics's net margin of --. Black Diamond Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

Black Diamond Therapeutics has a consensus price target of $10.75, signalling upside risk potential of 234.89%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Black Diamond Therapeutics, analysts believe Theriva Biologics is more attractive than Black Diamond Therapeutics.

Black Diamond Therapeutics has a beta of 2.711, which suggesting that the stock is 171.11% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Black Diamond Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Black Diamond Therapeutics quarterly revenues are $70M, which are larger than Theriva Biologics quarterly revenues of --. Black Diamond Therapeutics's net income of $56.5M is higher than Theriva Biologics's net income of -$4.3M. Notably, Black Diamond Therapeutics's price-to-earnings ratio is 53.50x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.